Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
about
Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
P2860
Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mantle cell lymphoma - does pr ...... survival for younger patients?
@en
Mantle cell lymphoma - does pr ...... survival for younger patients?
@nl
type
label
Mantle cell lymphoma - does pr ...... survival for younger patients?
@en
Mantle cell lymphoma - does pr ...... survival for younger patients?
@nl
prefLabel
Mantle cell lymphoma - does pr ...... survival for younger patients?
@en
Mantle cell lymphoma - does pr ...... survival for younger patients?
@nl
P2093
P2860
P1433
P1476
Mantle cell lymphoma - does pr ...... survival for younger patients?
@en
P2093
Anna Laurell
Arne Kolstad
Christian Geisler
Mantle Cell Lymphoma Subcommittee
Nordic Lymphoma Group
Riikka Räty
P2860
P304
P356
10.1080/10428190903040030
P577
2009-08-01T00:00:00Z